Application of neo-bioscore staging to predict the benefit of pertuzumab in HER2 positive early breast cancer

被引：0
|
作者：
Sanchez Escudero, L. [1 ]
Morales Pancorbo, D. [2 ]
Bayo, J. [3 ]
Aragon Manrique, I. [3 ]
机构：
[1] Hosp Juan Ramon Jimenez, Oncol, Huelva, Spain
[2] Hosp Juan Ramon Jimenez, Med, Huelva, Spain
[3] Hosp Juan Ramon Jimenez, Oncol Med, Huelva, Spain
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.478
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
197P
引用
收藏
页码：S442 / S443
页数：2
相关论文
共 50 条
  • [41] Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab in HER2 positive metastatic or locally recurrent unresectable breast cancer: assessment of toxicity
    Ajgal, Z.
    De Percin, S.
    Loirat, D.
    Pierga, J. Y.
    Campana, F.
    Fourquet, A.
    Kirova, Y.
    EUROPEAN JOURNAL OF CANCER, 2016, 57 : S50 - S51
  • [42] Role of pertuzumab in the treatment of HER2-positive breast cancer
    Hubalek, Michael
    Brantner, Christine
    Marth, Christian
    BREAST CANCER-TARGETS AND THERAPY, 2012, 4 : 65 - 73
  • [43] Pertuzumab (Perjeta) for HER2-Positive Metastatic Breast Cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2012, 54 (1395): : 59 - 60
  • [44] Is there a role for adjuvant pertuzumab in HER2-positive breast cancer?
    Mazzotta, Marco
    Barba, Maddalena
    Pizzuti, Laura
    Vici, Patrizia
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S281 - S284
  • [45] Pertuzumab biosimilar in HER2-positive metastatic breast cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2025, 85 (01) : 21 - 21
  • [46] Combination of eribulin with trastuzumab and pertuzumab for HER2 positive advanced or recurrent breast cancer: JBCRGM03
    Yamashita, Toshinari
    Kawaguchi, Hidetoshi
    Masuda, Norikazu
    Kitada, Masahiro
    Narui, Kazutaka
    Hattori, Masaya
    Yoshinami, Tetsuhiro
    Matsunami, Nobuki
    Yanagihara, Kazuhiro
    Nagashima, Takeshi
    Bando, Hiroko
    Yano, Hiroshi
    Hasegawa, Yoshie
    Nakamura, Rikiya
    Kashiwaba, Masahiro
    Morita, Satoshi
    Ohno, Shinji
    Toi, Masakazu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] Escalation and de-escalation in HER2 positive early breast cancer
    Dieci, Maria Vittoria
    Vernaci, Grazia
    Guarneri, Valentina
    CURRENT OPINION IN ONCOLOGY, 2019, 31 (01) : 35 - 42
  • [48] Pertuzumab, Trastuzumab, Docetaxel: a single istitution clinical exeperience for Her2 positive metastatic breast cancer (mBC)
    Martines, C.
    Lavenia, G.
    Salice, P.
    Latteri, F.
    Commendatore, O.
    Sambataro, D.
    Burrafato, G.
    Mattina, M.
    Amadio, P.
    Bordonaro, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [49] Delayed breast cancer surgery in HER2 positive breast cancer
    Hur, Ho
    Le, Amy
    Chang, Helena R.
    CANCER RESEARCH, 2020, 80 (04)
  • [50] Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer
    Hong, Joohyun
    Park, Yeon Hee
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
12345